NCT07907796 Propofol-Ketamine Versus Sevoflurane for Laryngeal Mask Anesthesia in Pediatric Cardiac Catheterization
| NCT ID | NCT07907796 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | Rawalpindi Institute of Cardiology |
| Condition | Propofol |
| Study Type | INTERVENTIONAL |
| Enrollment | 68 participants |
| Start Date | 2026-10-24 |
| Primary Completion | 2027-01-24 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 68 participants in total. It began in 2026-10-24 with a primary completion date of 2027-01-24.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Children undergoing cardiac catheterization will be given anesthesia using either a combination of propofol and ketamine or sevoflurane gas. The time taken to fall asleep will be recorded. During the procedure, anesthesia will be maintained to keep the child asleep and comfortable. After the procedure, the time taken to remove the breathing device and the time required for recovery will be recorded. In the recovery area, children will be assessed for emergence delirium (agitation, restlessness, or confusion while waking up from anesthesia) at 0, 5, 10, 15, and 60 minutes. Children who develop significant emergence delirium will receive an appropriate dose of medication to manage the condition, provided there are no medical reasons to avoid its use.
Eligibility Criteria
Inclusion Criteria: * Weighing 10-30kg * ASA I-III of either sex * Undergoing cardiac catheterization Exclusion Criteria: * History of Drug Allergy * Pre-existing Asthma * Renal or Hepatic dysfunction * Difficult/prolonged intubation * Congenital airway abnormalities
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07907796 clinical trial?
This trial is open to participants of all sexes, aged 2 Years or older, up to 12 Years, studying Propofol. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07907796 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07907796 currently recruiting?
Yes, NCT07907796 is actively recruiting participants. Contact the research team at drnasreenqaisrani@gmail.com for enrollment information.
Where is the NCT07907796 trial being conducted?
This trial is being conducted at Rawalpindi, Pakistan.
Who is sponsoring the NCT07907796 clinical trial?
NCT07907796 is sponsored by Rawalpindi Institute of Cardiology. The trial plans to enroll 68 participants.